Targeting the fibroblast growth factor receptor family in cancer

Cancer Treatment Reviews

Volumn 46, Issue , 2016, Pages 51-62

  Hallinan, Niamh ^a   Finn, Stephen ^a   Cuffe, Sinead ^a   Rafee, Shereen ^a   O'Byrne, Kenneth ^b   Gately, Kathy ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

EGFR; FGF ligand; FGFR; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTINEOPLASTIC AGENT; AZD 4547; BRIVANIB ALANINATE; CEDIRANIB; DOVITINIB; ERDAFITINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTOR 6; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR; INCB 054828; INFIGRATINIB; KERATINOCYTE GROWTH FACTOR; LENVATINIB; LUCITANIB; LY 2874455; NINTEDANIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BILE DUCT CARCINOMA; BREAST CANCER; CANCER GENETICS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DOWN REGULATION; ENDOMETRIUM CANCER; FATIGUE; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYELOPROLIFERATIVE DISORDER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84963959509     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.03.015     Document Type: Review

References (137)

1. Bregman M.D., Sipes N.J. Transformation-related growth factors and their receptors. Int J Cell Cloning 1986, 4:224-236.
2. Bottcher R.T., Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005, 26:63-77.
3. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
4. Helsten T., Elkin S., Arthur E., Tomson B.N., Carter J., Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res 2016 Jan 1, 22(1):259-267.
5. Lieu C., Heymach J., Overman M., Tran H., Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011, 17:6130-6139.
6. Azuma K., Kawahara A., Sonoda K., Nakashima K., Tashiro K., Watari K., et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget 2014, 5:5908-5919.
7. Herrera-Abreu M.T., Pearson A., Campbell J., Shnyder S.D., Knowles M.A., Ashworth A., et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discovery 2013, 3:1058-1071.
8. Saito S., Morishima K., Ui T., Hoshino H., Matsubara D., Ishikawa S., et al. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer 2015, 15:82.
9. Tiseo M., Gelsomino F., Alfieri R., Cavazzoni A., Bozzetti C., De Giorgi A.M., et al. FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev 2015, 41:527-539.
10. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discovery 2009, 8:235-253.
11. Goetz R., Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013, 14:166-180.
12. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
13. Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci USA 2004, 101:935-940.
14. Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H., Chan A.M., et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992, 89:246-250.
15. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005, 16:179-186.
16. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
17. Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci 2011, 68:951-964.
18. Trueb B., Zhuang L., Taeschler S., Wiedemann M. Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues. J Biol Chem 2003, 278:33857-33865.
19. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
20. Gallo L.H., Nelson K.N., Meyer A.N., Donoghue D.J. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev 2015, 26(4):425-449.
21. Ahmad I., Iwata T., Leung H.Y. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 2012, 1823:850-860.
22. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
23. Byron S.A., Gartside M.G., Wellens C.L., Mallon M.A., Keenan J.B., Powell M.A., et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 2008, 68:6902-6907.
24. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162.
25. Yu K., Herr A.B., Waksman G., Ornitz D.M. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000, 97:14536-14541.
26. Dutt A., Salvesen H.B., Chen T.H., Ramos A.H., Onofrio R.C., Hatton C., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008, 105:8713-8717.
27. Fearon A.E., Gould C.R., Grose R.P. FGFR signalling in women's cancers. Int J Biochem Cell Biol 2013, 45:2832-2842.
28. Liao R.G., Jung J., Tchaicha J., Wilkerson M.D., Sivachenko A., Beauchamp E.M., et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013, 73:5195-5205.
29. Heney N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992, 19:429-433.
30. Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63:8108-8112.
31. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
32. Tomlinson D.C., Baldo O., Harnden P., Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213(1):91-98.
33. van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Human Genet 2002, 10:819-824.
34. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61:1265-1268.
35. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Amoros A., Tardon A., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
36. Miyake M., Sugano K., Sugino H., Imai K., Matsumoto E., Maeda K., et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010, 101:250-258.
37. Gust K.M., McConkey D.J., Awrey S., Hegarty P.K., Qing J., Bondaruk J., et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther 2013, 10.1158/1535-7163.
38. Ross J.S., Wang K., Al-Rohil R.N., Nazeer T., Sheehan C.E., Otto G.A., et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 2014 Aug, 3(4):835-844.
39. Guancial E.A., Werner L., Bellmunt J., Bamias A., Choueiri T.K., Ross R., et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 2014, 3(4):835-844.
40. Rodriguez-Vida A., Saggese M., Hughes S., Rudman S., Chowdhury S., Smith N.R. Complexity of FGFR signalling in metastatic urothelial cancer. J Hematol Oncol 2015, 8:119.
41. Palma N., Morris J.C., Ali S.M., Ross J.S., Pal S.K. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. Eur Urol 2015, 68(1):168-170.
42. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
43. Marks J.L., McLellan M.D., Zakowski M.F., Lash A.E., Kasai Y., Broderick S., et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2007, 2:e426.
44. Roidl A., et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010, 29(10):1543-1552.
45. Taylor J.G., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009 Nov 2, 119(11):3395-3407.
46. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem J 2011, 437:199-213.
47. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
48. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998, 18:84-87.
49. Reiter A., Sohal J., Kulkarni S., Chase A., Macdonald D.H., Aguiar R.C., et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998, 92:1735-1742.
50. Wu Y.M., Su F., Kalyana-Sundaram S., Khazanov N., Ateeq B., Cao X., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discovery 2013, 3:636-647.
51. Capelletti M., Dodge M.E., Ercan D., Hammerman P.S., Park S.I., Kim J., et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 2014, 20:6551-6558.
52. Sia D., Losic B., Moeini A., Cabellos L., Hao K., Revill K., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015, 6:6087.
53. Borad M., Champion M.D., Egan J.B., Liang W.S., Fonseca R., Bryce A.H., et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014, 10:e1004135.
54. Arai Y., Totoki Y., Hosoda F., Shirota T., Hama N., Nakamura H., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013, 59:1427-1434.
55. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
56. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2012, 22(4):795-803.
57. Liang G., Liu Z., Wu J., Cai Y., Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012, 33:531-541.
58. Koole K., Brunen D., van Kempen P.M., Noorlag R., de Bree R., Lieftink C., et al. FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 2016.
59. Goke F., Bode M., Franzen A., Kirsten R., Goltz D., Goke A., et al. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol 2013, 26:1298-1306.
60. Goke F., Franzen A., Hinz T.K., Marek L.A., Yoon P., Sharma R., et al. FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin Cancer Res 2015, 21:4356-4364.
61. Jacquemier J., Adelaide J., Parc P., Penault-Llorca F., Planche J., deLapeyriere O., et al. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer 1994, 59:373-378.
62. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
63. Jang M., Kim E., Choi Y., Lee H., Kim Y., Kim J., et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012, 14:R115.
64. Gelsi-Boyer V., Orsetti B., Cervera N., Finetti P., Sircoulomb F., Rouge C., et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005, 3:655-667.
65. Elbauomy Elsheikh S., Green A.R., Lambros M.B., Turner N.C., Grainge M.J., Powe D., et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007, 9:R23.
66. Murphy T., Darby S., Mathers M.E., Gnanapragasam V.J. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010, 220:452-460.
67. Hamaguchi A., Tooyama I., Yoshiki T., Kimura H. Demonstration of fibroblast growth factor receptor-I in human prostate by polymerase chain reaction and immunohistochemistry. Prostate 1995, 27:141-147.
68. Acevedo V.D., Gangula R.D., Freeman K.W., Li R., Zhang Y., Wang F., et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007, 12:559-571.
69. Schildhaus H.U., Heukamp L.C., Merkelbach-Bruse S., Riesner K., Schmitz K., Binot E., et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 2012, 25:1473-1480.
70. Heist R.S., Mino-Kenudson M., Sequist L.V., Tammireddy S., Morrissey L., Christiani D.C., et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thoracic Oncol 2012, 7:1775-1780.
71. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2. 62ra93.
72. Cihoric N., Savic S., Schneider S., Ackermann I., Bichsel-Naef M., Schmid R.A., et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer 2014, 110:2914-2922.
73. Cheng C.L., Thike A.A., Tan S.Y., Chua P.J., Bay B.H., Tan P.H. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat 2015, 151:99-111.
74. Kim H.S., Lee S.E., Bae Y.S., Kim D.J., Lee C.G., Hur J., et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 2015, 6(4):2562-2572.
75. Guagnano V., Kauffmann A., Wohrle S., Stamm C., Ito M., Barys L., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discovery 2012, 2:1118-1133.
76. Goldstein M., Meller I., Issakov J., Orr-Urtreger A. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia 2006, 8(5):332-343.
77. Mayr D., Kanitz V., Anderegg B., Luthardt B., Engel J., Löhrs U., et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006, 126(1):101-109.
78. Tomlinson D.C., Lamont F.R., Shnyder S.D., Knowles M.A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69(11):4613-4620.
79. Tomlinson D.C., Knowles M.A. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 2010, 177(5):2379-2386.
80. Turner N., Lambros M.B., Horlings H.M., Pearson A., Sharpe R., Natrajan R., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023.
81. Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J Biol Chem 2009, 284:6227-6240.
82. Matsumoto K., Arao T., Hamaguchi T., Shimada Y., Kato K., Oda I., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012, 106:727-732.
83. Deng N., Goh L.K., Wang H., Das K., Tao J., Tan I.B., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.
84. Su X., Zhan P., Gavine P.R., Morgan S., Womack C., Ni X., et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 2014, 110:967-975.
85. Inokuchi M., Fujimori Y., Otsuki S., Sato Y., Nakagawa M., Kojima K. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. Gastroenterol Res Practice 2015, 2015:796380.
86. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008, 68:2340-2348.
87. Koole K., van Kempen P.M., Swartz J.E., Peeters T., van Diest P.J., Koole R., et al. Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med 2016 Feb, 5(2):275-284.
88. Wang Y., Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997, 3:887-893.
89. Becker D., Meier C.B., Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989, 8:3685-3691.
90. Becker D., Lee P.L., Rodeck U., Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 1992, 7:2303-2313.
91. Siddiqi I., Funatomi H., Kobrin M.S., Friess H., Buchler M.W., Korc M. Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995, 215:309-315.
92. Kornmann M., Ishiwata T., Beger H.G., Korc M. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene 1997, 15:1417-1424.
93. Yamanaka Y., Friess H., Buchler M., Beger H.G., Uchida E., Onda M., et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993, 53:5289-5296.
94. Kornmann M., Beger H.G., Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998, 17:169-175.
95. Memarzadeh S., Xin L., Mulholland D.J., Mansukhani A., Wu H., Teitell M.A., et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007, 12:572-585.
96. Buhmeida A., Dallol A., Merdad A., Al-Maghrabi J., Gari M.A., Abu-Elmagd M.M., et al. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour Biol 2014, 35:2817-2824.
97. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002, 160:2295-2307.
98. Nagamatsu H., Teishima J., Goto K., Shikuma H., Kitano H., Shoji K., et al. FGF19 promotes progression of prostate cancer. Prostate 2015, 75:1092-1101.
99. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 2008, 99:1319-1325.
100. Zhao Y., Zhang Z.Y. The mechanism of dephosphorylation of extracellular signal-regulated kinase 2 by mitogen-activated protein kinase phosphatase 3. J Biol Chem 2001, 276:32382-32391.
101. Casci T., Vinos J., Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell 1999, 96:655-665.
102. Kovalenko D., Yang X., Nadeau R.J., Harkins L.K., Friesel R. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 2003, 278:14087-14091.
103. Sorkin A., Goh L.K. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008, 314:3093-3106.
104. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2:294-307.
105. Tiong K.H., Mah L.Y., Leong C.O. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 2013, 18:1447-1468.
106. Haugsten E.M., Sorensen V., Brech A., Olsnes S., Wesche J. Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. J Cell Sci 2005, 118:3869-3881.
107. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008, 8:835-850.
108. Cho J.Y., Guo C., Torello M., Lunstrum G.P., Iwata T., Deng C., et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 2004, 101:609-614.
109. Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discovery 2013, 3:264-279.
110. Tan L., Wang J., Tanizaki J., Huang Z., Aref A.R., Rusan M., et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci USA 2014, 111:E4869-E4877.
111. Andre F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013, 19:3693-3702.
112. Soria J.C., DeBraud F., Bahleda R., Adamo B., Andre F., Dienstmann R., et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014, 25(11):2244-2251.
113. Abu-Khalaf Maysa M., Mayer Ingrid A., Tankersley Chris, Moy Jadine, Allen Andrew R., Vogel Charles L., et al. A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. J Clin Oncol 2015, 33(15).
114. Knights V., Cook S.J. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010, 125:105-117.
115. Gavine P.R., Mooney L., Kilgour E., Thomas A.P., Al-Kadhimi K., Beck S., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012, 72:2045-2056.
116. National Cancer Institute. Lung-MAP Launches: First Precision Medicine Trial from National Clinical Trials Network 2014.
117. Wolf J., LoRusso P., Cambridge R., Perez J., Tabernero J., Hidalgo M. A phase 1 dose escalation study of NVP-BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumours. AACR 2012.
118. Tabernero J., Bahleda R., Dienstmann R., Adamo B., Gazzah A., Infante J.R. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014, 32. 5s (suppl; abstr 2501).
119. Sootome H, Fujioka Y, Miura A, Fuijita H, Hirai H, Utsugiet T. TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors. In: AACR-NCI-EORTC International Conference; 2013.
120. Ochiiwa H, Fujita H, Itoh K, Sootoome H, Hashimoto A, Fujioka Y, et al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. In: AACR-NCI-EORTC International; 2013.
121. Liu P.C.C., Wu L., Koblish H., Bowman K., Zhang Y., Klabe R. Preclinical characterization of the selective FGFR inhibitor INCB054828. AACR 2015.
122. Harding T.C., Long L., Palencia S., Zhang H., Sadra A., Hestir K. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013, 5. 178ra39.
123. Bai A., Meetze K., Vo N.Y., Kollipara S., Mazsa E.K., Winston W.M., et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 2010, 70:7630-7639.
124. Gust K.M., McConkey D.J., Awrey S., Hegarty P.K., Qing J., Bondaruk J., et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther 2013, 12:1245-1254.
125. Du X., Lin B.C., Wang Q.R., Li H., Ingalla E., Tien J., et al. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. Clin Cancer Res 2014, 20:6324-6335.
126. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Investig 2009, 119:1216-1229.
127. Sierra J.R., Cepero V., Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010, 9:75.
128. Sohl C.D., Ryan M.R., Luo B., Frey K.M., Anderson K.S. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. ACS Chem Biol 2015, 10(5):1319-1329.
129. Norman R.A., Schott A.K., Andrews D.M., Breed J., Foote K.M., Garner A.P., et al. Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem 2012, 55:5003-5012.
130. Chell V., Balmanno K., Little A.S., Wilson M., Andrews S., Blockley L., et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013, 32(25):3059-3070.
131. Byron S.A., Chen H., Wortmann A., Loch D., Gartside M.G., Dehkhoda F., et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 2013, 15(8):975-988.
132. Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.Y., Marchetti A., et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012, 18(3):748-757.
133. Ang D., Ballard M., Beadling C., Warrick A., Schilling A., O'Gara R. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets. Diagn Mol Pathol 2014.
134. Issa A., Gill J.W., Heideman M.R., Sahin O., Wiemann S., Dey J.H., et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 2013, 15:R8.
135. Harbinski F., Craig V.J., Sanghavi S., Jeffery D., Liu L., Sheppard K.A., et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discovery 2012, 2:948-959.
136. Ware K.E., Marshall M.E., Heasley L.R., Marek L., Hinz T.K., Hercule P., et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 2010, 5:e14117.
137. Ware K.E., Hinz T.K., Kleczko E., Singleton K.R., Marek L.A., Helfrich B.A., et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013, 2:e39.